Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis

Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis

Immune checkpoint inhibitor (ICI)-induced colitis is one of the known complications of therapies targeting cytotoxic programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and programmed cell death ligand 1 (PD-L1). ICI-associated colitis is routinely treated w...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Leilei Fang, Changqin Liu, Xiaomin Sun, Zhanju Liu
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2022-06-01
Sarja:Frontiers in Oncology
Aiheet:
anti-tumor necrosis factor-α
colitis
durvalumab
immune checkpoint inhibitor
programmed cell death ligand 1
vedolizumab
Linkit:https://www.frontiersin.org/articles/10.3389/fonc.2022.925964/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.925964/full

Samankaltaisia teoksia